The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer

Dong, Ke; Li, Hanwei; Zhang, Yi; An, Yufeng; Fu, Hanjiang; Fang, Xuedong; Zheng, Xiaofei

doi:10.18632/oncotarget.15628

Cited by 79 publications

(78 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, there is increasing evidence that combinations of several tumour markers may have improved diagnostic accuracy . Thus, we constructed different signatures by combining the plasma candidate lncRNAs into a 4‐lncRNA signature, 4 − 1 lncRNA signatures and 2‐lncRNA signatures and generated ROC curves as shown in Figures b and c .…”

Section: Resultsmentioning

confidence: 99%

“…Notably, there is increasing evidence that combinations of several tumour markers may have improved diagnostic accuracy. 17,18 Thus, we constructed different signatures by combining the plasma candidate lncRNAs into a 4-lncRNA signature, 4 − 1 lncRNA signatures and 2-lncRNA signatures and generated ROC curves as shown in Figures 2b and 2c. The results indicated that the combination of ZFAS1, SNHG11, LINC00909 and LINC00654, with an AUC of 0.937 (95% CI: 0.892-0.982), showed the greatest ability to differentiate CRC patients from controls in comparison with any other combination or the four lncRNAs alone.…”

Section: Evaluation Of the Crc Diagnostic Value Using Different Combimentioning

confidence: 99%

See 1 more Smart Citation

Circulating lncRNA SNHG11 as a novel biomarker for early diagnosis and prognosis of colorectal cancer

Zhou

Wang

et al. 2019

Intl Journal of Cancer

141

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer mortality worldwide. Emerging evidence indicates that tumour cells release substantial amounts of RNA into the bloodstream, in which RNA strongly resists RNases and is present at sufficient levels for quantitative analyses. Our study aimed to discover blood‐based markers for the early detection of CRC and to ascertain their efficiency in discriminating healthy controls, patients with polyps and adenomas and cancer patients. We first analysed and screened ZFAS1, SNHG11, LINC00909 and LINC00654 in a bioinformatics database and then collected clinical plasma samples for preliminary small‐scale analysis and further large‐scale verification. We then explored the mechanism of dominant lncRNA SNHG11 expression in CRC by in vitro and in vivo assays. The combination of ZFAS1, SNHG11, LINC00909 and LINC00654 showed high diagnostic performance for CRC (AUC: 0.937), especially early‐stage disease (AUC: 0.935). Plasma levels of the four candidate lncRNAs were significantly reduced in postoperative samples compared to preoperative samples. A panel including these four lncRNAs performed well in distinguishing patient groups with different stages of colon disease, and SNHG11 exhibited the greatest diagnostic ability to identify precancerous lesions and early‐stage tumour formation. Mechanistically, high SNHG11 expression promotes proliferation and metastasis by targeting the Hippo pathway. Taken together, the data indicate that SNHG11 may be a novel therapeutic target for the treatment of CRC and a potential biomarker for the early detection of CRC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Evaluation Of the Crc Diagnostic Value Using Different Combimentioning

confidence: 99%

Circulating lncRNA SNHG11 as a novel biomarker for early diagnosis and prognosis of colorectal cancer

Zhou

Wang

et al. 2019

Intl Journal of Cancer

141

View full text Add to dashboard Cite

show abstract

“…Indeed, researchers have identified three circulating lncRNAs, Linc00152, CFLAR-AS1, and POU3F3, as potential biomarkers for predicting the development of human esophageal squamous cell carcinoma [27]. Furthermore, levels of the circulating lncRNAs AK001058, INHBA-AS1, MIR4435-2HG, UCA1, and CEBPA-AS1 were significantly higher in gastric cancer patients compared with healthy controls [28]. However, to the best of our knowledge, no clinical studies have reported on circulating lncRNAs in OSCC to date.…”

Section: Discussionmentioning

confidence: 99%

SCCA, TSGF, and the Long Non-Coding RNA AC007271.3 are Effective Biomarkers for Diagnosing Oral Squamous Cell Carcinoma

Shao¹,

Huang²,

Zheng³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Oral squamous cell carcinoma (OSCC) is one of the most lethal malignancies worldwide and the most common type of oral cancer, characterized by invasive growth, frequent regional metastases, high recurrence, and poor prognosis. In the current study, we investigated the use of long non-coding RNAs (lncRNAs), tumor-specific growth factor (TSGF), and squamous cell carcinoma antigen (SCCA) as potential biomarkers for OSCC screening. Methods: LncRNA expression was measured by microarray analysis in three sets of OSCC and paired normal mucosal tissues. The potential lncRNAs involved in OSCC development were investigated by bioinformatics and verification experiments. We also determined the expression of these potential biomarkers in tissue and serum samples in a case–control study of 80 OSCC cases and 70 controls. Receiver operating characteristics, decision curve analysis, and the combined detection of lncRNA AC007271.3, TSGF, and SCCA were carried out to screen for OSCC biomarkers. Results: A total of 691 lncRNAs (433 upregulated and 258 downregulated) were differentially expressed in OSCC tissues compared with normal controls (p< 0.05). Based on Gene Ontology and pathway analysis, we selected four differentially expressed lncRNAs (AC007271.3, AC007182.6, LOC283481, and RP11-893F2.9), and showed that aberrant AC007271.3 levels in OSCC patients were significantly associated with clinical stage, especially in early-stage disease, in an expanded case–control study. The combination of AC007271.3 and SCCA (AUC=0.902, p< 0.001) showed significantly better ability to discriminate between OSCC and controls compared with SCCA or AC007271.3 alone. Serum AC007271.3, SCCA, and TSGF levels could also discriminate between OSCC and normal controls with sensitivities of 77.6%, 55.0%, and 63.3%, and specificities of 84.5%, 93.3%, and 66.7%, respectively. Conclusions: These results suggest that AC007271.3, SCCA, and TSGF could be novel circulating biomarkers for the determination of OSCC. However, further validation in large-scale prospective studies is necessary.

show abstract

“…18 Recently, LINC00978 was reported as one of the 4 serum lncRNAs that might serve as a panel for gastric cancer diagnosis. 19 However, the biological functions and potential underlying mechanisms of LINC00978 in gastric cancer progression remain unclear.…”

Section: Discussionmentioning

confidence: 99%

“…Deng et al 18 found that high level of LINC00978 predicted poor prognosis in breast cancer patients. Recently, Ke et al 19 demonstrated that a combination of circulating lncRNAs including MIR4435-2HG in plasma can serve as diagnostic markers for gastric cancer. However, the precise biological function and potential underlying mechanism of LINC00978 in gastric cancer have not been well characterized.…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA LINC00978 promotes cancer growth and acts as a diagnostic biomarker in gastric cancer

Huang

Zang

et al. 2017

Cell Proliferation

View full text Add to dashboard Cite

Objectives: Long noncoding RNAs (lncRNAs) play important roles in cancer development and progression. The deregulated expression of LINC00978 has been reported in human cancers. However, the expression pattern and biological roles of LINC00978 in gastric cancer (GC) remain unclear. In this study, we investigated the potential roles and clinical value of LINC00978 in gastric cancer. Materials and methods:QRT-PCR was performed to investigate the expression of LINC00978 in gastric cancer cell lines, tissues and serum samples. Cell counting, colony formation, transwell migration and matrigel invasion assays were performed to determine the effects of shRNA-mediated knockdown of LINC00978 on gastric cancer cell functions. In vivo tumour growth assay was also conducted. Flow cytometry, immunohistochemistry, western blot and qRT-PCR were used for potential mechanism study.Results: LINC00978 expression level was elevated in GC tumour tissues, serum samples and cell lines. The expression level of LINC00978 was significantly correlated with tumour size (P = 0.02), lymphatic metastasis (P = 0.009) and TNM stage (P = 0.009). LINC00978 knockdown inhibited the proliferation of GC cells by suppressing cell cycle progression and inducing apoptosis. LINC00978 knockdown also inhibited the migration and invasion of GC cells. In addition, LINC00978 knockdown inhibited the activation of TGF-β/SMAD signalling pathway and the process of epithelial-mesenchymal transition (EMT) in GC cells. Moreover, the in vivo tumorigenicity of LINC00978 knockdown GC cells in mice was significantly decreased.Conclusions: LINC00978 promotes gastric cancer progression and may serve as a potential biomarker for GC.

show abstract

The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer

Cited by 79 publications

References 40 publications

Circulating lncRNA SNHG11 as a novel biomarker for early diagnosis and prognosis of colorectal cancer

Circulating lncRNA SNHG11 as a novel biomarker for early diagnosis and prognosis of colorectal cancer

SCCA, TSGF, and the Long Non-Coding RNA AC007271.3 are Effective Biomarkers for Diagnosing Oral Squamous Cell Carcinoma

Long noncoding RNA LINC00978 promotes cancer growth and acts as a diagnostic biomarker in gastric cancer

Contact Info

Product

Resources

About